Teacher Retirement System of Texas acquired a new position in shares of TESARO Inc (NASDAQ:TSRO) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 10,497 shares of the biopharmaceutical company’s stock, valued at approximately $870,000.
A number of other institutional investors have also made changes to their positions in TSRO. Perceptive Advisors LLC lifted its position in shares of TESARO by 8.1% during the third quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after purchasing an additional 29,100 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in TESARO during the third quarter worth about $33,911,000. Vident Investment Advisory LLC raised its stake in TESARO by 379.4% during the third quarter. Vident Investment Advisory LLC now owns 5,652 shares of the biopharmaceutical company’s stock worth $729,000 after acquiring an additional 4,473 shares during the period. Sectoral Asset Management Inc acquired a new stake in TESARO during the third quarter worth about $19,339,000. Finally, Gabelli Funds LLC raised its stake in TESARO by 203.0% during the fourth quarter. Gabelli Funds LLC now owns 10,000 shares of the biopharmaceutical company’s stock worth $829,000 after acquiring an additional 6,700 shares during the period.
Several equities research analysts have commented on the stock. BidaskClub upgraded shares of TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday. Morgan Stanley lowered their price objective on shares of TESARO from $156.00 to $146.00 and set an “overweight” rating on the stock in a research note on Thursday, March 1st. ValuEngine upgraded shares of TESARO from a “sell” rating to a “hold” rating in a research note on Friday, March 2nd. Credit Suisse Group restated an “in-line” rating and set a $141.00 target price (down from $150.00) on shares of TESARO in a report on Wednesday, February 28th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $122.00 target price (down from $224.00) on shares of TESARO in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TESARO has a consensus rating of “Buy” and an average target price of $133.39.
In other news, VP Grant C. Bogle sold 1,809 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $54.85, for a total value of $99,223.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Leon O. Moulder, Jr. purchased 5,000 shares of TESARO stock in a transaction dated Friday, March 2nd. The stock was bought at an average price of $56.93 per share, with a total value of $284,650.00. Following the acquisition, the chief executive officer now directly owns 1,018,828 shares of the company’s stock, valued at $58,001,878.04. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. 34.60% of the stock is currently owned by corporate insiders.
TESARO Inc (TSRO) traded down $1.91 during trading hours on Wednesday, reaching $62.69. 818,293 shares of the company’s stock were exchanged, compared to its average volume of 1,244,701. TESARO Inc has a 52-week low of $52.20 and a 52-week high of $168.92. The firm has a market capitalization of $3,410.00, a price-to-earnings ratio of -6.83 and a beta of 1.40. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. The business had revenue of $48.02 million for the quarter, compared to the consensus estimate of $51.78 million. analysts expect that TESARO Inc will post -9.54 earnings per share for the current fiscal year.
WARNING: “Teacher Retirement System of Texas Invests $870,000 in TESARO Inc (NASDAQ:TSRO)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://ledgergazette.com/2018/03/14/teacher-retirement-system-of-texas-acquires-new-position-in-tesaro-inc-tsro.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.